

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

pC034 - LwCas13a-msfGFP-2A-Blast

RRID:Addgene_91924

Type: Plasmid

Proper Citation

RRID:Addgene_91924

Plasmid Information

URL: <http://www.addgene.org/91924>

Proper Citation: RRID:Addgene_91924

Insert Name: LwCas13a

Organism: Leptotrichia wadei

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:28976959](#)

Vector Backbone Description: Backbone Size:8216; Vector Backbone:pFUGW; Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: pC034 - LwCas13a-msfGFP-2A-Blast

Record Creation Time: 20220422T222622+0000

Record Last Update: 20260902T050522+0000

Ratings and Alerts

No rating or validation information has been found for pC034 - LwCas13a-msfGFP-2A-Blast.

No alerts have been found for pC034 - LwCas13a-msfGFP-2A-Blast.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mathiesen BT, et al. (2025) A simple inland culture system provides insights into ascidian post-embryonic developmental physiology. *Open biology*, 15(1), 240340.

Pardi ML, et al. (2025) SARS-CoV-2 Nsp1-Resistant Modified RNA for the Creation of Nsp1-Responsive Systems. *ACS synthetic biology*, 14(6), 2386.

Cai Y, et al. (2022) Complex genomic patterns of abasic sites in mammalian DNA revealed by a high-resolution SSiNGLe-AP method. *Nature communications*, 13(1), 5868.

Saifullah , et al. (2022) Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, 24(9), 1785.

Johnson MC, et al. (2022) Lack of Cas13a inhibition by anti-CRISPR proteins from *Leptotrichia* prophages. *Molecular cell*, 82(11), 2161.

Singh A, et al. (2021) Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-Cas13a. *Current gene therapy*, 21(3), 270.

Xu D, et al. (2020) A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response. *Scientific reports*, 10(1), 1794.

Konermann S, et al. (2018) Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. *Cell*, 173(3), 665.